The Study of the BX Velocity Stent in the Treatment of De Novo Artery Lesions.

This is a multicenter ,prospective, randomized double blind study. This study has a 2-arm design assessing the safety and effectiveness of the sirolimus-coated Bx VELOCITY™ stent to the uncoated Bx VELOCITY™ stent, both mounted on Raptor® Stent Delivery Systems. A total of 100 patients will be entered in the study and will be randomized on a 1:1 basis. Patients who meet the eligibility criteria will be either randomized to Treatment A or Treatment B. Neither the investigator nor the patient will know which stent will be implanted. Patients will be followed at 30 days, 6, 9, and 12 months, and at 2, 3, 4 and 5 years post-procedure, with all patients undergoing repeat angiography at 8 months. Additionally, medical costs associated with the index hospitalization and length of stay, and repeat hospitalizations and costs associated with other relevant medical resource use during the 5 years follow-up period will be collected and analyzed.

Inclusion criteria

• Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II) OR patients with documented silent ischemia;
• Single treatment of de novo lesion in a major coronary artery in patients with single or multi-vessel disease; patients with multiple lesions can be included only if the other lesions do not require treatment;
• Target vessel diameter at the lesion site is >=2.50mm and <=3.0mm in diameter (visual estimate);
• Target lesion is >=15mm and <=32mm in length (visual estimate);
• Target lesion stenosis is >50% and <100% (visual estimate);

Exclusion criteria

• Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK >2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remains above normal at the time of treatment;
• Has unstable angina classified as Braunwald III B or C and A I-II-III, or is having a peri infarction;
• Unprotected left main coronary disease with >=50% stenosis;
• Significant (>50%) stenoses proximal or distal to the target lesion that might require revascularization or impede runoff;
• Have an ostial target lesion;
• Angiographic evidence of thrombus within target lesion;
• Heavily calcified lesion which cannot be successfully predilated;
• Documented left ventricular ejection fraction <=25%.